title: Identification of CCK-A receptors on chief cells with use of a novel, highly selective ligand.
abstract: Functional studies suggest that guinea pig chief cells have both cholecystokinin-A (CCK-A) and CCK-B receptors (CCK-A-R and CCK-B-R, respectively). However, all efforts to directly characterize the specific CCK-A-R using binding have been unsuccessful. Recent studies describe specific CCK-A-R agonists such as A-71378 ([desamino-Nle28,31-(N-methyl)Asp32]CCK heptapeptide]. In the present study, [D-Tyr-Gly]A-71378 was synthesized, which has > 300-fold selectivity for CCK-A-R and can be iodinated. [D-Tyr-Gly]A-71378 was equipotent to A-71378 in stimulating pepsinogen release from purified guinea pig chief cells. Binding of 125I-labeled [D-Tyr-Gly]A-71378 was saturable and specific. Potencies for inhibiting binding were as follows: [D-Tyr-Gly]A-71378 = A-71378 = 4x CCK octapeptide (CCK-8) > 1,000x des(SO4)-CCK-8, gastrin. In contrast, for 125I-gastrin binding they were CCK-8 > gastrin-17-I > des(SO4)-CCK-8 >> A-71378 or [D-Tyr-Gly]A-71378. Binding of [D-Tyr-Gly]A-71378 was best fitted by a two-site model. In contrast, 125I-gastrin binding was fitted with a single-site model. For inhibiting binding of 125I-[D-Tyr-Gly]A-71378, the CCK antagonists had relative affinities of L-364,718 >> L-365,260, and the reverse was true with 125I-gastrin. Correlation of binding with changes in biological activity suggested low-affinity CCK-A-R were mediating these changes. These results demonstrate directly for the first time that guinea pig chief cells possess CCK-A-R and CCK-B-R. The pharmacology of these CCK-A-R resembles those on other tissues. This novel, highly selective CCK-A ligand should be useful because it will identify CCK-A-R when they make up as little as 0.2% of the total CCK receptor number.
authors.affiliation: Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1804, USA.
authors.forename: T K
authors.initials: TK
authors.lastname: Pradhan
authors.forename: J M
authors.initials: JM
authors.lastname: Qian
authors.forename: V E
authors.initials: VE
authors.lastname: Sutliff
authors.forename: S A
authors.initials: SA
authors.lastname: Mantey
authors.forename: R T
authors.initials: RT
authors.lastname: Jensen
mesh_terms: D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D020109:Devazepide; D005753:Gastric Mucosa / Q000378:metabolism*; D005755:Gastrins / Q000037:antagonists & inhibitors; D006168:Guinea Pigs; D008024:Ligands; D008297:Male; D009842:Oligopeptides / Q000378:metabolism; D010179:Pancreas / Q000378:metabolism; D010435:Pepsinogens / Q000378:metabolism; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin / Q000145:classification / Q000378:metabolism*; D012844:Sincalide / Q000494:pharmacology; D013270:Stomach / Q000166:cytology
chemical_list: C093347:(Tyr-Gly)A-71378; D001570:Benzodiazepinones; D005755:Gastrins; D008024:Ligands; D009842:Oligopeptides; D010435:Pepsinogens; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin; C063897:A 71378; C058121:L 365260; C013550:gastrin 17; D020109:Devazepide; D012844:Sincalide